Adjuvant activity of the catalytic A1 domain of cholera toxin for retroviral antigens delivered by GeneGun

Clinical and Vaccine Immunology

Volumn 18, Issue 6, 2011, Pages 922-930

  Bagley, Kenneth C ^a   Lewis, George K ^b,c   Fouts, Timothy R ^a  

^a Profectus Biosciences   (United States)

^b INSTITUTE OF HUMAN VIROLOGY   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA TOXIN; CHOLERA TOXIN A1; DNA VACCINE; GAG PROTEIN; GAMMA INTERFERON; GLYCOPROTEIN GP 120; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; RECOMBINANT PROTEIN; SIMIAN IMMUNODEFICIENCY VIRUS ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIGEN ANTIBODY REACTION; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG DELIVERY SYSTEM; GENE GUN; GENE GUN IMMUNIZATION; HUMORAL IMMUNITY; IMMUNOGENICITY; MACACA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; TOXIN ANALYSIS;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; BIOLISTICS; CHOLERA TOXIN; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; MACACA; MICE; MICE, INBRED BALB C; SAIDS VACCINES; VACCINES, DNA;

EID: 79957986558     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.05019-11     Document Type: Article

References (54)

1. Agren, L., B. Lowenadler, and N. Lycke. 1998. A novel concept in mucosal adjuvanticity: the CTA1-DD adjuvant is a B cell-targeted fusion protein that incorporates the enzymatically active cholera toxin A1 subunit. Immunol. Cell Biol. 76:280-287.
2. Agren, L., et al. 2000. The ADP-ribosylating CTA1-DD adjuvant enhances T cell-dependent and independent responses by direct action on B cells involving anti-apoptotic Bcl-2- and germinal center-promoting effects. J. Immunol. 164:6276-6286. (Pubitemid 30408808)
3. Aihara, H., and J. Miyazaki. 1998. Gene transfer into muscle by electroporation in vivo. Nat. Biotechnol. 16:867-870.
4. Arrington, J., et al. 2002. Plasmid vectors encoding cholera toxin or the heat-labile enterotoxin from Escherichia coli are strong adjuvants for DNA vaccines. J. Virol. 76:4536-4546. (Pubitemid 34309589)
5. Bagley, K. C., S. F. Abdelwahab, R. G. Tuskan, T. R. Fouts, and G. K. Lewis. 2002. Cholera toxin and heat-labile enterotoxin activate human monocyte-derived dendritic cells and dominantly inhibit cytokine production through a cyclic AMP-dependent pathway. Infect. Immun. 70:5533-5539.
6. Bagley, K. C., S. F. Abdelwahab, R. G. Tuskan, and G. K. Lewis. 2003. An enzymatically active a domain is required for cholera-like enterotoxins to induce a long-lived blockade on the induction of oral tolerance: new method for screening mucosal adjuvants. Infect. Immun. 71:6850-6856.
7. Bagley, K. C., et al. 2003. Immunogenicity of DNA vaccines that direct the coincident expression of the 120 kDa glycoprotein of human immunodeficiency virus and the catalytic domain of cholera toxin. Vaccine 21:3335-3341. (Pubitemid 36700432)
8. Cassel, D., and Z. Selinger. 1977. Mechanism of adenylate cyclase activation by cholera toxin: inhibition of GTP hydrolysis at the regulatory site. Proc. Natl. Acad. Sci. U. S. A. 74:3307-3311.
9. Chow, Y. H., W. L. Huang, W. K. Chi, Y. D. Chu, and M. H. Tao. 1997. Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2. J. Virol. 71:169-178.
10. De Haan, L., and T. R. Hirst. 2004. Cholera toxin: a paradigm for multifunctional engagement of cellular mechanisms. Mol. Membr. Biol. 21:77-92.
11. Donnelly, J. J., B. Wahren, and M. A. Liu. 2005. DNA vaccines: progress and challenges. J. Immunol. 175:633-639.
12. Feltquate, D. M., S. Heaney, R. G. Webster, and H. L. Robinson. 1997. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J. Immunol. 158:2278-2284.
13. Forde, G. M. 2005. Rapid-response vaccines - does DNA offer a solution? Nat. Biotechnol. 23:1059-1062. (Pubitemid 41486383)
14. Fynan, E. F., et al. 1993. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc. Natl. Acad. Sci. U. S. A. 90:11478-11482.
15. Giuliani, M. M., et al. 1998. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity. J. Exp. Med. 187:1123-1132.
16. Glenn, G. M., et al. 2007. Transcutaneous immunization with heat-labile enterotoxin: development of a needle-free vaccine patch. Expert Rev. Vaccines 6:809-819. (Pubitemid 47607855)
17. Glenn, G. M., M. Rao, G. R. Matyas, and C. R. Alving. 1998. Skin immunization made possible by cholera toxin. Nature 391:851.
18. Glenn, G. M., et al. 1998. Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge. J. Immunol. 161:3211-3214.
19. Glenn, G. M., T. Scharton-Kersten, R. Vassell, G. R. Matyas, and C. R. Alving. 1999. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants. Infect. Immun. 67:1100-1106.
20. Glenn, G. M., et al. 2000. Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat. Med. 6:1403-1406.
21. Haynes, J. R., J. Arrington, L. Dong, R. P. Braun, and L. G. Payne. 2006. Potent protective cellular immune responses generated by a DNA vaccine encoding HSV-2 ICP27 and the E. coli heat labile enterotoxin. Vaccine 24:5016-5026.
22. Hazes, B., and R. J. Read. 1997. Accumulating evidence suggests that several AB-toxins subvert the endoplasmic reticulum-associated protein degradation pathway to enter target cells. Biochemistry 36:11051-11054.
23. Heyningen, S. V. 1974. Cholera toxin: interaction of subunits with ganglioside GM1. Science 183:656-657.
24. Hochreiter, R., et al. 2001. The influence of CpG motifs on a protein or DNA-based Th2-type immune response against major pollen allergens Bet v 1a, Phl p 2 and Escherichia coli-derived beta-galactosidase. Int. Arch. Allergy Immunol. 124:406-410.
25. Jang, H. S., T. H. Cho, Y. S. Jang, and P. H. Choung. 1999. Administration of multiple cytokine genes with anti-tumor activity inhibits both tumor incidence and tumor growth. Yonsei Med. J. 40:355-362.
26. Jobling, M. G., and R. K. Holmes. 2000. Identification of motifs in cholera toxin A1 polypeptide that are required for its interaction with human ADP-ribosylation factor 6 in a bacterial two-hybrid system. Proc. Natl. Acad. Sci. U. S. A. 97:14662-14667.
27. Jones, S., et al. 2009. DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial. Vaccine 27:2506-2512.
28. Keeney, T. S., L. E. Nomura, H. T. Maecker, and K. J. Sastry. 2003. Flow cytometric analysis of macaque whole blood for antigen-specific intracellular cytokine production by T lymphocytes. J. Med. Primatol. 32:23-30.
29. Kim, J. J., et al. 1998. Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens. Eur. J. Immunol. 28:1089-1103.
30. Kim, J. J., et al. 2000. Coimmunization with IFN-gamma or IL-2, but not IL-13 or IL-4 cDNA can enhance Th1-type DNA vaccine-induced immune responses in vivo. J. Interferon Cytokine Res. 20:311-319. (Pubitemid 30169743)
31. Liu, M. A. 2003. DNA vaccines: a review. J. Intern. Med. 253:402-410.
32. Lu, S., S. Wang, and J. M. Grimes-Serrano. 2008. Current progress of DNA vaccine studies in humans. Expert Rev. Vaccines 7:175-191.
33. Lu, Y., et al. 1999. Macrophage inflammatory protein-1alpha (MIP-1alpha) expression plasmid enhances DNA vaccine-induced immune response against HIV-1. Clin. Exp. Immunol. 115:335-341.
34. Lycke, N. 1997. The mechanism of cholera toxin adjuvanticity. Res. Immunol. 148:504-520.
35. Lycke, N., and J. Holmgren. 1986. Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens. Immunology 59:301-308. (Pubitemid 16021162)
36. Lycke, N., T. Tsuji, and J. Holmgren. 1992. The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. Eur. J. Immunol. 22:2277-2281.
37. Maecker, H. T. 2004. Cytokine flow cytometry. Methods Mol. Biol. 263:95-108.
38. Maecker, H. T., et al. 2001. Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J. Immunol. Methods 255:27-40.
39. Maino, V. C., and H. T. Maecker. 2004. Cytokine flow cytometry: a multiparametric approach for assessing cellular immune responses to viral antigens. Clin. Immunol. 110:222-231.
40. Moore, J. P., and R. F. Jarrett. 1988. Sensitive ELISA for the gp120 and gp160 surface glycoproteins of HIV-1. AIDS Res. Hum. Retroviruses 4:369-379.
41. Moore, J. P., et al. 1990. Characterisation of recombinant gp120 and gp160 from HIV-1: binding to monoclonal antibodies and sCD4. AIDS 4:307-315. (Pubitemid 20157012)
42. Nomura, L. E., E. D. deHaro, L. N. Martin, and H. T. Maecker. 2003. Optimal preparation of rhesus macaque blood for cytokine flow cytometric analysis. Cytometry A 53:28-38.
43. Ohtomo, N., T. Muraoka, A. Tashiro, Y. Zinnaka, and K. Amako. 1976. Size and structure of the cholera toxin molecule and its subunits. J. Infect. Dis. 133(Suppl.):31-40.
44. Oliveira, S. C., et al. 1999. Immunological properties of gene vaccines delivered by different routes. Braz. J. Med. Biol. Res. 32:207-214.
45. Rodighiero, C., et al. 1999. Structural basis for the differential toxicity of cholera toxin and Escherichia coli heat-labile enterotoxin. Construction of hybrid toxins identifies the A2-domain as the determinant of differential toxicity. J. Biol. Chem. 274:3962-3969.
46. Ryan, E. J., et al. 2000. Modulation of innate and acquired immune responses by Escherichia coli heat-labile toxin: distinct pro- and anti-inflammatory effects of the nontoxic AB complex and the enzyme activity. J. Immunol. 165:5750-5759.
47. Sharpe, M., et al. 2007. Protection of mice from H5N1 influenza challenge by prophylactic DNA vaccination using particle mediated epidermal delivery. Vaccine 25:6392-6398. (Pubitemid 47090232)
48. Sin, J. I., et al. 1999. IL-12 gene as a DNA vaccine adjuvant in a herpes mouse model: IL-12 enhances Th1-type CD4+ T cell-mediated protective immunity against herpes simplex virus-2 challenge. J. Immunol. 162:2912-2921.
49. Tuting, T. 1999. The immunology of cutaneous DNA immunization. Curr. Opin. Mol. Ther. 1:216-225.
50. Vajdy, M., and N. Y. Lycke. 1992. Cholera toxin adjuvant promotes longterm immunological memory in the gut mucosa to unrelated immunogens after oral immunization. Immunology 75:488-492.
51. Walker, J. M., H. T. Maecker, V. C. Maino, and L. J. Picker. 2004. Multicolor flow cytometric analysis in SIV-infected rhesus macaque. Methods Cell Biol. 75:535-557.
52. Weiss, R., et al. 2002. Gene gun bombardment with gold particles displays a particular Th2-promoting signal that over-rules the Th1-inducing effect of immunostimulatory CpG motifs in DNA vaccines. Vaccine 20:3148-3154.
53. Xin, K. Q., et al. 1999. Immunization of RANTES expression plasmid with a DNA vaccine enhances HIV-1-specific immunity. Clin. Immunol. 92:90-96.
54. Youssef, S., et al. 2000. C-C chemokine-encoding DNA vaccines enhance breakdown of tolerance to their gene products and treat ongoing adjuvant arthritis. J. Clin. Invest. 106:361-371.